Anti-CD40 antibodies in antiphospholipid syndrome and systemic lupus erythematosus

Panayiotis G.Vlachoyiannopoulos; Clio P. Mavragani; Efi Bourazopoulou; Anthi V. Balitsari; John G. Routsias

doi:10.1160/TH04-02-0135

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2004; 92(06): 1303-1311
DOI: 10.1160/TH04-02-0135

Blood Coagulation, Fibrinolysis and Cellular Haemostasis

Schattauer GmbH

Anti-CD40 antibodies in antiphospholipid syndrome and systemic lupus erythematosus

Panayiotis G.Vlachoyiannopoulos

¹Department of Pathophysiology, Medical School, National University of Athens, Athens, Greece

,

Clio P. Mavragani^*

¹Department of Pathophysiology, Medical School, National University of Athens, Athens, Greece

,

Efi Bourazopoulou^*

¹Department of Pathophysiology, Medical School, National University of Athens, Athens, Greece

,

Anthi V. Balitsari

¹Department of Pathophysiology, Medical School, National University of Athens, Athens, Greece

,

John G. Routsias

¹Department of Pathophysiology, Medical School, National University of Athens, Athens, Greece

› Institutsangaben

Abstract

Summary

Anti-β2glycoprotein I (anti-β2GPI) antibodies constitute the main autoantibody specificity in the sera of patients with antiphospholipid syndrome (APS). There is evidence that antiβ2GPI antibodies induce the precoagulant activity of the endothelium by cross-linking the β2 glycoprotein I (β2GPI) on the cell surface. Since β2GPI lacks intracellular domains, homology with other molecules such as CD40 that could initiate signaling, was extensively searched. A 86% homology between the amino acid position 239-245 of the CD40 and 7-13 of the β2glycoprotein was found. The CD40 peptide corresponding to amino acids 239-245 of the CD40 molecule was synthesized and coupled to a multiple antigenic peptide carrier. Antibodies to CD40 peptide were found in 61.5% APS patients (n=39), in 72.7% of systemic lupus erythematosus (SLE) positive for anti β2GPI antibodies (n=11) and 31.6% of SLE negative for antiβ2GPI antibodies (n=19), but not in rheumatoid arthritis patients (n=28) or controls (n=36). Antibodies to CD40 peptide were associated with arterial thrombosis and/or brain microinfarcts. Affinity purified anti-CD40 peptide antibodies as well as affinity purified anti-β2GPI antibodies recognized both, the β2GPI and the CD40 peptide. The specificity of this recognition was confirmed with homologous and heterologous inhibition experiments. Confocal microscopy experiments demonstrated this cross-recognition of CD40 and β2GPI molecules, by the purified anti-CD40 peptide antibodies, at the protein level. Thus, antibodies reacting with the β2GPI can react and potentially activate different cells which express CD40 molecules at their surface.

Keywords

CD40 peptides - antibodies - antiphospholipid syndrome - β2 glycoprotein I - systemic lupus erythematosus

Volltext

Referenzen

References
1 Wilson WA, Gharavi AE, Koike T. et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999; 42: 1309-11.
2 Petrovas C, Vlachoyiannopoulos PG, Kordossis T. et al. Anti-phospholipid antibodies in HIV infection and SLE with or without antiphospholipid syndrome: comparisons of phospholipid specificity, avidity and reactivity with beta2-GPI. J Autoimmun 1999; 13: 347-55.
3 Fleck RA, Rapaport SI, Rao LV. Anti-prothrombin antibodies and the lupus anticoagulant. Blood 1988; 72: 512-9.
4 Nakamura N, Ban T, Yamaji K. et al. Localization of the apoptosis-inducing activity of lupus anticoagulant in an annexin V-binding antibody subset. J Clin Invest 1998; 101: 1951-9.
5 Nakamura N, Ban T, Yamaji K. et al. Localization of the apoptosis-inducing activity of lupus anticoagulant in an annexin V-binding antibody subset. J Clin Invest 1998; 101: 1951-9.
6 Vlachoyiannopoulos PG, Petrovas C, Tektonidou M. et al. Antibodies to beta 2-glycoprotein-I: urea resistance, binding specificity, and association with thrombosis. J Clin Immunol 1998; 18: 380-91.
7 Pierangeli SS, Colden-Stanfield M, Liu X. et al. Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo . Circulation 1999; 99: 1997-2002.
8 Branch DW, Rodgers GM. Induction of endothelial cell tissue factor activity by sera from patients with antiphospholipid syndrome: a possible mechanism of thrombosis. Am J Obstet Gynecol 1993; 168: 206-10.
9 Simantov R, LaSala JM, Lo SK. et al. Activation of cultured vascular endothelial cells by antiphospholipid antibodies. J Clin Invest 1995; 96: 2211-19.
10 Del Papa N, Raschi E, Catelli L. et al. Endothelial cells as a target for antiphospholipid antibodies: role of anti-beta 2 glycoprotein I antibodies. Am J Reprod Immunol 1997; 38: 212-17.
11 Dunoyer-Geindre S, de Moerloose P, Galve-de Rochemonteix B. et al. NFkappaB is an essential intermediate in the activation of endothelial cells by anti-beta(2)-glycoprotein 1 antibodies. Thromb Haemost 2002; 88: 851-7.
12 Forastiero R, Martinuzzo M, Carreras LO. et al. Anti-beta2 glycoprotein I antibodies and platelet activation in patients with antiphospholipid antibodies: association with increased excretion of platelet-derived thromboxane urinary metabolites. Thromb Haemost 1998; 79: 42-5.
13 Bouma B, de Groot PG, van den Elsen JM. et al. Adhesion mechanism of human beta(2)-glycoprotein I to phospholipids based on its crystal structure. EMBO J 1999; 18: 5166-74.
14 Iverson GM, Victoria EJ, Marquis DM. Antibeta2 glycoprotein I (beta2GPI) autoantibodies recognize an epitope on the first domain of beta2GPI. Proc Natl Acad Sci U S A 1998; 95: 15542-6.
15 McNeeley PA, Dlott JS, Furie RA. et al. Beta2-glycoprotein I-dependent anticardiolipin antibodies preferentially bind the amino terminal domain of beta2-glycoprotein I. Thromb Haemost 2001; 86: 590-5.
16 Bavendiek U, Libby P, Kilbride M. et al. Induction of tissue factor expression in human endothelial cells by CD40 ligand is mediated via activator protein 1, nuclear factor kappa B, and Egr-1. J Biol Chem 2002; 277: 25032-9.
17 Rushworth SA, Bravery CA, Thompson S. Human CD154 induces activation of porcine endothelial cells and up-regulation of MHC class II expression. Transplantation 2001; 72: 127-32.
18 Inwald DP, McDowall A, Peters MJ. et al. CD40 is constitutively expressed on platelets and provides a novel mechanism for platelet activation. Circ Res 2003; 92: 1041-8.
19 Schonbeck U, Mach F, Sukhova GK. et al. CD40 ligation induces tissue factor expression in human vascular smooth muscle cells. Am J Pathol 2000; 156: 7-14.
20 Kehry MR. CD40-mediated signaling in B cells. Balancing cell survival, growth, and death. J Immunol 1996; 156: 2345-8.
21 Tan EM, Cohen AS, Fries JF. et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-7.
22 Arnett FC, Edworthy SM, Bloch DA. et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
23 Sakarellos-Daitsiotis M, Tsikaris V, Vlachoyiannopoulos PG. et al. Peptide carriers: A helicoid type sequential oligopeptide carrier (SOCn) for multiple anchoring of antigenic/immunogenic peptides. Methods 1999; 19: 133-41.
24 McNeil HP, Simpson RJ, Chesterman CN. et al. Antiphospholipid antibodies are directed against a complex antigen that induces a lipidbinding inhibitor of coagulation: β2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990; 87: 4120-4.
25 McNeil HP, Krillis SA, Chesterman CN. Purification of antiphospholipid antibodies using a new affinity method. Thrombosis Res 1988; 52: 641-8.
26 McNeil HP, Chesterman CN, Krilis SA. Binding specificity of lupus anticoagulants and anticardiolipin antibodies. Thrombosis Res 1988; 52: 609-19.
27 Vidalain PO, Azocar O, Servet-Delprat C. et al. CD40 signaling in human dendritic cells is initiated within membrane rafts. EMBO J 2000; 19: 3304-13.
28 Hanissian SH, Geha RS. Jak3 is associated with CD40 and is critical for CD40 induction of gene expression in B cells. Immunity 1997; 06: 379-87.
29 Arch RH, Gedrich RW, Thompson CB. Tumor necrosis factor receptor-associated factors (TRAFs) – a family of adapter proteins that regulates life and death. Genes Dev 1998; 12: 2821-30.
30 Revy P, Hivroz C, Andreu G. et al. Activation of the Janus kinase 3-STAT5a pathway after CD40 triggering of human monocytes but not of resting B cells. J Immunol 1999; 163: 787-93.
31 Werneburg BG, Zoog SJ, Dang TT. et al. Molecular characterization of CD40 signaling intermediates. J Biol Chem 2001; 276: 43334-42.
32 Zoog SJ, Papov VV, Pullen SS. et al. Signaling and protein associations of a cell permeable CD40 complex in B cells. Mol Immunol 2004; 40: 681-94.
33 Nomura J, Inui S, Yamasaki T. et al. Anti-CD40 monoclonal antibody induces the proliferation of murine B cells as a B-cell mitogen through a distinct pathway from receptors for antigens or lipopolysaccharide. Immunol Lett 1995; 45: 195-203.
34 Morio T, Hanissian SH, Bacharier LB. et al. Ku in the cytoplasm associates with CD40 in human B cells and translocates into the nucleus following incubation with IL-4 and anti-CD40 mAb. Immunity 1999; 11: 339-48.
35 Casellas R, Nussenzweig A, Wuerffel R. et al. Ku80 is required for immunoglobulin isotype switching. EMBO J 1998; 17: 2404-11.
36 Amengual O, Atsumi T, Khamashta MA. Tissue factor in antiphospholipid syndrome: shifting the focus from coagulation to endothelium. Rheumatology 2003; 42: 1029-31.